Biotech Values

[DewDiligence]

Presuming both Merck and Vertex get their PI's approved I was just speculating Merck may somehow market boceprevir in a package with PEG-Intron and try to compete on price…

I don’t think MRK will do that; if they did, the backlash would IMO be loud and immediate.

…even with the longer treatment duration.

It’s not clear that Boceprevir will have a materially longer average course of therapy than Telaprevir when all is said and done. In the treatment-naïve setting, both drugs will likely be prescribed using a response-guided regimen.